Corona Remedies IPO
Corona Remedies IPO is priced at ₹1008–₹1062 per share with an issue size of ₹655.37 crore. The IPO opens on Dec 8, 2025 and closes on Dec 10, 2025, with a lot size of 14 shares and a minimum investment of ₹14,868.
Corona Remedies Limited IPO
- IPO Dates
- Dec 8, 2025 – Dec 10, 2025
- Price band
- ₹1008-1062 per equity share
- Minimum Investment
- ₹14,868
- Issue size
- ₹655.37 Cr
- Lot size
- 14
- Allotment Date
- Dec 11, 2025
- Listing
- Dec 15, 2025
- Listing At
- BSE, NSE
IPO timeline
-
Dec 8, 2025
Open Date
Completed
-
Dec 10, 2025
Close Date
Completed
-
Dec 11, 2025
Allotment Date
Completed
-
Dec 15, 2025
Listing Date
Completed
Corona Remedies IPO Expected Premium (Grey Market Trend)
Corona Remedies IPO GMP today is ₹240. Grey market premium (GMP) indicates expected listing sentiment.
Corona Remedies IPO expected premium (also known as grey market premium or GMP) indicates current market sentiment and potential listing expectations.
Expected Premium provided in this website is derived from market rumors. It is not a guaranteed indicator of the actual listing price and should be interpreted with caution.
Corona Remedies IPO Live Subscription Details
View Subscription DetailsCorona Remedies IPO subscription status shows demand across QIB, NII, and retail categories, helping investors understand participation levels.
Last updated:Corona Remedies IPO Essentials
Corona Remedies IPO Details
Corona Remedies IPO is priced at ₹1008-1062 per share with a total issue size of 655.37 crore. The IPO has a lot size of 14 shares and will be listed on BSE and NSE.
- Issue price
- ₹1008-1062 per equity share
- Lot size
- 14 shares
- Face value
- ₹10 Per Equity Share
- Issue size
- Offer For Sale : 61,71,101 shares(aggregating up to ₹655.37 Cr)
- Total issue size
- 61,71,101 shares
(aggregating up to ₹655.37 crore) - Offer for sale (OFS)
- 61,71,101 shares
(aggregating up to ₹655.37 crore) - Listing at
- BSE, NSE
- Listing date
- Registrar
- Bigshare Services Pvt Ltd
- Lead manager
-
JM Financial Ltd, IIFL Capital Services Ltd, Kotak Mahindra Capital Co.Ltd, Kotak Mahindra Capital Co.Ltd.
Market Lot Size
Investors can bid for a minimum of 14 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 14 | ₹14,868 |
| Retail(max) | 13 | 182 | ₹1,93,284 |
| sHNI(min) | 14 | 196 | ₹2,08,152 |
| sHNI(max) | 67 | 938 | ₹9,96,156 |
| sHNI(min) | 68 | 952 | ₹10,11,024 |
Corona Remedies IPO Reservation
Corona Remedies IPO reservation details show category-wise allocation of shares. Out of the total 6171101 shares, approximately 19.8% are reserved for QIB, 14.86% for NII, 10% for retail investors, 0.94% for employees, and 29.73% for anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 1834804 (29.73%) | |
| QIB Shares Offered | 1221729 (19.8%) | |
| NII (HNI) Shares Offered | 916960 (14.86%) | |
| bHNI > ₹10L | 611307 (10%) | 3119 |
| sHNI < ₹10L | 305653 (5%) | 1559 |
| Retail Shares Offered | 2139573 (10%) | 152827 |
| Employee Shares Offered | 58036 (0.94%) | |
| Total Shares Offered | 6171101 (100%) |
Corona Remedies IPO Analytics
Corona Remedies IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Corona Remedies IPO Subscription Status
Corona Remedies IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO is currently subscribed 9.9x, indicating strong demand across investor categories.
| As on |
NII
sHNI
|
Retail | Total | |
|---|---|---|---|---|
| Shares Offered / Reserved |
9,16,960
3,05,653
|
21,39,573 | 43,36,298 | |
|
Day 1
08-12-25 05:00 PM
|
0.00 x |
0.84x
0.53x
1.45x
|
0.95 x | 0.67 x |
|
Day 2
09-12-25 05:00 PM
|
1.76 x |
28.28x
29.02x
26.80x
|
6.76 x | 9.87 x |
Corona Remedies Valuations
Earnings
- EPS Pre IPO
- ₹24.43/-
- EPS Post IPO
- ₹30.21/-
- P/E Pre IPO
- 43.47
- P/E Post IPO
- 35.15
Returns
- ROE
- 27.50%
- ROCE
- 41.32%
- RoNW
- 24.65%
- PAT Margin
- 12.49%
Fundamentals
- Debt / Equity
- 0.10
- Price / Book
- 10.71
- Market Cap
- 6495.20 Cr.
Corona Remedies Financials( In Crs.)
| 30-Jun-25 | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 | |
|---|---|---|---|---|
| Assets | 1012.38 | 929.86 | 830.58 | 595.02 |
| Revenue | 348.56 | 1202.35 | 1020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| Net Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves & Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
Corona Remedies Company & Offer Insights
About Corona Remedies
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women's healthcare, cardiology, pain management, urology, and other therapeutic areas.
The diversified portfolio of the company as of December 2024 comprises 67 brands across therapeutic areas such as women's healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals, including vitamins/minerals/nutrition, gastrointestinal, and respiratory.The company has a pan-India marketing and distribution network with 2,598 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, thus consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
Presently, the company owns two manufacturing facilities located in the states of Gujarat.
As of December 31, 2024, the company had 88 R&D employees.
Corona Remedies Promoter(s)
Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta, Ankur Kirtikumar Mehta are the company's promoters of Corona Remedies.
Corona Remedies IPO Issue Objectives
- •
Corona Remedies IPO - Anchor Investors
Corona Remedies raises nearly Rs 195 crore from 15 anchor investors.
Of the total anchor allotment, 13.59 lakh shares worth Rs 144.4 crore were allotted to 11 domestic mutual funds including SBI Mutual Fund, ICICI Prudential MF, Kotak Mahindra AMC, Axis Mutual Fund, Mirae Asset, Aditya Birla Sun Life AMC, Invesco, DSP MF, Franklin India and Tata MF that have applied through their total of 13 schemes.
The other investors that participated in the anchor book included SBI Life Insurance, Ashoka India, FSSA Indian Subcontinent Fund, and IIFL Asset Management.
Corona Remedies IPO - Peers Comparison
| P/B Ratio | P/E Ratio | RoNW | Revenue(in Cr.) | |
|---|---|---|---|---|
| Corona Remedies | N/A | N/A | 24.6% | 1196 |
| Abbott India | N/A | 45.1 | 33.4% | 6409 |
| Alkem Lab | N/A | 31.3 | 18.0% | 12964 |
| Eris Life | N/A | 61.8 | 12.2% | 2893 |
| Glaxosmithkline | N/A | 46.8 | 47.5% | 3749 |
| J B Chemicals | N/A | 42.6 | 19.2% | 3917 |
| Mankind | N/A | 45.7 | 13.8% | 12207 |
| Pfizer | N/A | 29.6 | 18.2% | 2281 |
| Sanofi | N/A | 24.4 | 48.0% | 2013 |
| Torrent | N/A | 65.9 | 25.1% | 11516 |
Corona Remedies IPO - Strengths and Risks
Corona Remedies IPO strengths and risks highlight key business factors, financial position, and market sentiment that may impact investor interest.
Strengths
Risks
Contact Information
Contact Details
Corona Remedies
+91 79 4023 3000
complianceofficer@coronaremedies.com
https://www.coronaremedies.com/
CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej, Ahmedabad, Gujarat, 380059
Registrar Contact Details
Bigshare Services Pvt Ltd
+91-22-6263 8200
Frequently Asked Questions
Click any question to reveal the answer
Corona Remedies IPO is a book-built IPO worth ₹655.37 crore. The price band is ₹1008–₹1062 per share. The IPO opens on Dec 8, 2025 and closes on Dec 10, 2025. It will be listed on BSE and NSE. Bigshare Services Pvt Ltd is the registrar.
The price band of Corona Remedies IPO is ₹1008 to ₹1062 per share.
The lot size of Corona Remedies IPO is 14 shares.
The minimum investment for Corona Remedies IPO is approximately ₹14,868 based on the upper price band .
Corona Remedies IPO opens on Dec 8, 2025 and closes on Dec 10, 2025.
The allotment date of Corona Remedies IPO is Dec 11, 2025.
Corona Remedies IPO is expected to be listed on Dec 15, 2025, on BSE and NSE .
The Grey Market Premium (GMP) for Corona Remedies IPO is ₹240-250 as of Dec 7, 2025. Based on the upper price band of ₹1062, the estimated listing price is ₹1,302.
Corona Remedies IPO valuation snapshot: P/E 35.15, EPS ₹30.21/-, P/B 10.71, RoNW 24.65%, and market cap 6495.20 Cr.
To apply for Corona Remedies IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Corona Remedies IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Corona Remedies IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Corona Remedies IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Corona Remedies IPO allotment status on IPO Ji for quick and easy access.